ArticleHeart and vessels2026
Combined prognostic value of elevated lipoprotein(a) and severe calcification for limb outcomes after endovascular therapy.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein(a) [Lp(a)] and vascular calcification have each been associated with poor outcomes in lower extremity arterial disease (LEAD). This study investigated whether elevated Lp(a) levels and severe calcification have combined prognostic value for major adverse limb events (MALE) after endovascular therapy (EVT). We retrospectively analyzed 145 patients who underwent EVT. Patients were classified according to the number of Lp(a)/ Peripheral Arterial Calcium Scoring System (PACSS) risk markers: elevated Lp(a) (≥ 30 mg/dL) and PACSS grade 4. The primary endpoint was 1-year MALE incidence. MALE occurred in 17 patients during follow-up. Patients were classified into three groups according to the number of Lp(a)/PACSS risk markers. The cumulative incidence of MALE differed significantly among the three groups (overall P = 0.032). Compared with the 0 risk-marker group, the 1 risk-marker group and the 2 risk-marker group had significantly higher risks of MALE (hazard ratio [HR], 3.175; 95% confidence interval [CI], 1.064-9.475; P = 0.038; and HR, 4.803; 95% CI 1.146-20.128; P = 0.032, respectively). A significant trend toward higher MALE risk was observed with an increasing number of risk markers (P for trend = 0.012). Elevated Lp(a) and severe calcification may identify a subgroup at higher risk of MALE after EVT. Integrating Lp(a) measurement with anatomical assessment by PACSS may provide exploratory insights into risk stratification.
Indexed as
Identifiers
42501118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.